株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

コンパニオン診断の世界市場 - 分析と予測:2020年~2030年

Global Companion Diagnostics Market: Focus on Technology, Application Area, Country Data (12 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

発行 BIS Research Inc. 商品コード 935848
出版日 ページ情報 英文 233 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
コンパニオン診断の世界市場 - 分析と予測:2020年~2030年 Global Companion Diagnostics Market: Focus on Technology, Application Area, Country Data (12 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日: 2020年05月07日 ページ情報: 英文 233 Pages
担当者のコメント
先進国、新興国におけるペットの普及により拡大を続けるコンパニオン診断(CDx)市場に着目した最新の調査レポートがBIS Researchよりリリースされました。2030年までのForecastをまとめております。
概要

世界のコンパニオン診断市場は、2030年までに75億3670万米ドルに達すると予測されています。

当レポートでは、世界のコンパニオン診断市場について調査分析し、市場概要、市場分析と予測、主要企業などについて、体系的な情報を提供しています。

目次

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 市場力学

  • 概要
  • アイスバーグ解析:世界のコンパニオン診断市場
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第5章 業界考察

  • 法的要件と枠組み:FDA別
  • 法的要件と枠組み:EMA別
  • 法的要件と枠組み:MHLW別

第6章 競合情勢

  • 合併と買収
  • 製品発売と製品アップデート
  • 相乗的活動
  • 事業拡大活動など
  • 製品承認
  • 市場シェア分析
  • 機会マッピング

第7章 世界のコンパニオン診断市場の概要

  • コンパニオン診断 (CDx) の分類
  • 歴史的観点におけるCDx
  • コンパニオン診断 (CDx) 開発の構成要素
  • コンパニオン診断 (CDx) の重要な応用
  • コンパニオン診断 (CDx) :将来の可能性

第8章 世界のコンパニオン診断市場:技術別

  • 概要
  • ポリメラーゼ連鎖反応 (PCR)
  • 免疫組織化学 (IHC)
  • ISH (in situ ハイブリダイゼーション)
  • 次世代シーケンシング (NGS)

第9章 世界のコンパニオン診断市場:適応分野別

  • 概要
  • 肺がん
  • 乳がん
  • 大腸がん
  • 白血病
  • 胃がん
  • 黒色腫
  • その他

第10章 世界のコンパニオン診断市場:地域別

  • 概要
  • 北米
  • アジア太平洋地域
  • その他の地域

第11章 企業プロファイル

図表

List of Tables

  • Table 8.1: PCR-Based Companion Diagnostics Manufacturers
  • Table 8.2: PCR-Based Companion Diagnostics Service Providers
  • Table 8.3: IHC-Based Companion Diagnostics Manufacturers
  • Table 8.4: IHC-Based Companion Diagnostics Service Providers
  • Table 8.5: ISH-Based Companion Diagnostics Manufacturers
  • Table 8.6: ISH-Based Companion Diagnostics Service Providers
  • Table 8.7: NGS-Based Companion Diagnostics Manufacturers
  • Table 8.8: NGS-Based Companion Diagnostics Service Providers
  • Table 9.1: Cancer Type - Incidence and Mortality
  • Table 9.2: Available Companion Diagnostic Tests for Lung Cancer
  • Table 9.3: Available Companion Diagnostic Tests for Breast Cancer
  • Table 9.4: Available Companion Diagnostic Tests for Colorectal Cancer
  • Table 9.5: Available Companion Diagnostic Tests for Leukemia
  • Table 9.6: Available Companion Diagnostic Tests for Stomach Cancer
  • Table 9.7: Available Companion Diagnostic Tests for Melanoma
  • Table 9.8: Available Companion Diagnostic Tests for Other Application Areas
  • Table 10.1: List of Cleared or Approved Companion Diagnostic Devices
  • Table 10.2: List of Cleared or Approved Companion Diagnostic Devices
  • Table 10.3: List of Cleared or Approved Companion Diagnostic Devices

List of Figures

  • Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Companion Diagnostics Market
  • Figure 3: Global Companion Diagnostics Market (by Technology), 2019 vs. 2030 ($Million)
  • Figure 4: Global Companion Diagnostics Market (by Application Area), 2019 vs. 2030 ($Million)
  • Figure 5: Global Companion Diagnostics Market Snapshot
  • Figure 2.1: Global Companion Diagnostics Market Segmentation
  • Figure 2.2: Global Companion Diagnostics Market Methodology Primary Research Methodology
  • Figure 3.1: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.2: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Iceberg Analysis - Global Companion Diagnostics Market
  • Figure 4.2: Impact Analysis
  • Figure 4.3: Cancer Incidence by WHO Region (2012) per 100,000
  • Figure 4.4: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 4.5: Fully Aligned Drug-Diagnostic Co-Development
  • Figure 4.6: CDx Leakage for Oncology
  • Figure 5.1: FDA Guidelines for CDx Approval
  • Figure 6.1: Share of Key Developments and Strategies, January 2014-February 2020
  • Figure 6.2: Product Launches Share (by Company), January 2014-February 2020
  • Figure 6.3: Synergistic Activities Share (by Company), January 2014-February 2020
  • Figure 6.4: Market Share Analysis for the Global Companion Diagnostics Market, 2019
  • Figure 6.5: Opportunity Mapping for Global Companion Diagnostics Market (by Technology), 2019-2030
  • Figure 6.6: Opportunity Mapping for Global Companion Diagnostics Market (by Application Area), 2019-2030
  • Figure 6.7: Opportunity Mapping for Global Companion Diagnostics Market (by Region), 2019-2030
  • Figure 7.1: Classification of Companion Diagnostics (CDx)
  • Figure 7.2: Evolution of Companion Diagnostics (CDx)
  • Figure 7.3: Components Required to Develop Companion Diagnostics
  • Figure 7.4: Applications of Companion Diagnostics (CDx)
  • Figure 7.5: Potential of Companion Diagnostics (CDx)
  • Figure 8.1: Global Companion Diagnostics Market (by Technology)
  • Figure 8.2: Global Companion Diagnostics Market (PCR Technology), 2019-2030
  • Figure 8.3: Total Market Size for PCR Companion Diagnostics (by Application Area), 2019 and 2030
  • Figure 8.4: Total Market Size for Immunohistochemistry (by Application Area), 2019 and 2030
  • Figure 8.5: Global Companion Diagnostics Market (IHC Technology), 2019-2030
  • Figure 8.6 Global Companion Diagnostics Market (ISH Technology), 2019-2030
  • Figure 8.7: Total Market Size for In-situ Hybridization (by Application Area), 2019 and 2030
  • Figure 8.8: Global Companion Diagnostics Market (NGS Technology), 2019-2030
  • Figure 8.9: Total Market Size for Next Generation Sequencing (by Application Area), 2019 and 2030
  • Figure 9.1: Global Companion Diagnostics Market (by Application Area), 2019-2030
  • Figure 9.2: Global Companion Diagnostics Market (Lung Cancer), 2019-2030
  • Figure 9.3: Total Market Size for Lung Cancer Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.4: Global Companion Diagnostics Market (Breast Cancer), 2019-2030
  • Figure 9.5: Total Market Size for Breast Cancer Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.6: Global Companion Diagnostics Market (Colorectal Cancer), 2019-2030
  • Figure 9.7: Total Market Size for Colorectal Cancer Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.8: Global Companion Diagnostics Market (Leukemia), 2019-2030
  • Figure 9.9: Total Market Size for Leukemia Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.10: Global Companion Diagnostics Market (Stomach Cancer), 2019-2030
  • Figure 9.11: Total Market Size for Stomach Cancer Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.12: Global Companion Diagnostics Market (Melanoma), 2019-2030
  • Figure 9.13: Total Market Size for Melanoma Companion Diagnostics (by Technology), 2019 and 2030
  • Figure 9.14: Global Companion Diagnostics Market (by Other Application Areas), 2019-2030
  • Figure 10.1: Global Companion Diagnostics Market (by Region), 2019 and 2030
  • Figure 10.2: Global Companion Diagnostics Market (by Region), 2019-2030
  • Figure 10.3: Global Companion Diagnostics Market Share (by Region), 2019
  • Figure 10.4: Global Companion Diagnostics Market Share (by Region), 2030
  • Figure 10.5: North America Companion Diagnostics Market, 2019-2030
  • Figure 10.6: North America: Market Dynamics
  • Figure 10.7: North America Companion Diagnostics Market (by Country), 2019-2030
  • Figure 10.8: U.S. Companion Diagnostics Market, 2019-2030
  • Figure 10.9: Canada Companion Diagnostics Market, 2019-2030
  • Figure 10.10: Europe Companion Diagnostics Market, 2019-2030
  • Figure 10.11: Europe: Market Dynamics
  • Figure 10.12: Europe Companion Diagnostics Market (by Country), 2019-2028
  • Figure 10.13: Germany Companion Diagnostics Market, 2019-2030
  • Figure 10.14: France Companion Diagnostics Market, 2019-2030
  • Figure 10.15: U.K. Companion Diagnostics Market, 2019-2030
  • Figure 10.16: Italy Companion Diagnostics Market, 2019-2030
  • Figure 10.17: Spain Companion Diagnostics Market, 2019-2030
  • Figure 10.18: Rest-of-Europe Companion Diagnostics Market, 2019-2030
  • Figure 10.19: Asia-Pacific Companion Diagnostics Market, 2019-2030
  • Figure 10.20: APAC: Market Dynamics
  • Figure 10.21: APAC Companion Diagnostics Market (by Country), 2019-2030
  • Figure 10.22: China Companion Diagnostics Market, 2019-2030
  • Figure 10.23: Japan Companion Diagnostics Market, 2019-2030
  • Figure 10.24: Australia Companion Diagnostics Market, 2019-2030
  • Figure 10.25: India Companion Diagnostics Market, 2019-2030
  • Figure 10.26: Singapore Companion Diagnostics Market, 2019-2030
  • Figure 10.27: RoAPAC Companion Diagnostics Market, 2019-2030
  • Figure 10.28: RoW Companion Diagnostics Market, 2019-2030
  • Figure 11.1: Total Number of Companies Profiled
  • Figure 11.2: Abbott Laboratories: Product Portfolio
  • Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 11.7: Abbott Laboratories: SWOT Analysis
  • Figure 11.8: Agilent Technologies, Inc.: Product Portfolio
  • Figure 11.9: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 11.10: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.11: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
  • Figure 11.12: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.13: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 11.14: ARUP Laboratories: Product Portfolio
  • Figure 11.15: ARUP Laboratories: SWOT Analysis
  • Figure 11.16: bioMerieux S.A.: Product Portfolio
  • Figure 11.17: bioMerieux S.A.: Overall Financials, 2016-2018
  • Figure 11.18: bioMerieux S.A.: Revenue (by Segment), 2016-2018
  • Figure 11.19: bioMerieux S.A.: Revenue (by Region), 2016-2018
  • Figure 11.20: bioMerieux S.A.: R&D Expenditure, 2016-2018
  • Figure 11.21: bioMerieux S.A.: SWOT Analysis
  • Figure 11.22: Danaher Corporation: Product Portfolio
  • Figure 11.23: Danaher Corporation: Overall Financials, 2016-2018
  • Figure 11.24: Danaher Corporation: Revenue (by Business Segment), 2016-2018
  • Figure 11.25: Danaher Corporation: Revenue (by Region), 2016-2018
  • Figure 11.26: Danaher Corporation: R&D Expenditure, 2016-2018
  • Figure 11.27: Danaher Corporation: SWOT Analysis
  • Figure 11.28: DiaCarta, Inc.: Product Portfolio
  • Figure 11.29: DiaCarta, Inc.: SWOT Analysis
  • Figure 11.30: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 11.31: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 11.32: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 11.33: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 11.34: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 11.35: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 11.36: ICON plc: Product Portfolio
  • Figure 11.37: ICON plc: Overall Financials, 2016-2018
  • Figure 11.38: ICON plc: Revenue (by Region), 2016-2018
  • Figure 11.39: ICON plc: SWOT Analysis
  • Figure 11.40: Illumina, Inc.: Product Portfolio
  • Figure 11.41: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 11.42: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.43: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 11.44: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 11.45: Illumina, Inc.: SWOT Analysis
  • Figure 11.46: Invivoscribe Technologies, Inc.: Product Portfolio
  • Figure 11.47: Invivoscribe Technologies, Inc.: SWOT Analysis
  • Figure 11.48: Myriad Genetics, Inc.: Product Portfolio
  • Figure 11.49: Myriad Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 11.50: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 11.51: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 11.52: Novogene Corporation.: Product Portfolio
  • Figure 11.53: Novogene Corporation: SWOT Analysis
  • Figure 11.54: QIAGEN N.V.: Product Portfolio
  • Figure 11.55: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 11.56: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 11.57: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 11.58: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 11.59: QIAGEN N.V.: SWOT Analysis
  • Figure 11.60: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 11.61: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 11.62: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
  • Figure 11.63: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
  • Figure 11.64: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 11.65: Thermo Fisher Scientific Inc.: SWOT Analysis
目次
Product Code: BH067B

Global Companion Diagnostics Market to Reach $7,536.7 Million by 2030

Key Questions Answered in this Report:

  • What are the long-term and short-term impacts of companion diagnostics on the human health continuum?
  • What are the major market drivers, challenges, and opportunities in the global companion diagnostics market?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global companion diagnostics market?
  • How is the patent landscape in the industry shaping up future technological trends?
  • How is each segment of the market expected to grow during the forecast period from 2020 to 2030?
  • Who are the leading players with significant offerings to the global companion diagnostics market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are challenges that are yet to be met by the global companion diagnostics market?

Global Companion Diagnostics Market Forecast, 2020-2030

The companion diagnostics industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.45% during the forecast period, 2020-2030. The global companion diagnostics market generated $1,764.7 million revenue in 2019, in terms of value. The global companion diagnostics market growth has been primarily attributed to the major drivers in this market such as growing incidence of cancer, growing demand for precision medicine, and co development of drug and diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include uncertain reimbursement scenario, weak synchronization between therapeutics and diagnostics in marketing and distribution channels.

Expert Quote

"North America is the leading contributor in the global companion diagnostics market and contributed approximately 56.69% to the global market value in 2019. This region is anticipated to grow at a significant CAGR during the forecast period 2020-2030 and continue dominating the global market in 2030. However, the Asia-Pacific region is expected to grow at the highest CAGR of 20.99% during the forecast period. In addition, the region of Europe also contributed a significant share of 25.95% to the global market in 2019."

Scope of the Market Intelligence on the Global Companion Diagnostics Market

The companion diagnostics research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of the report primarily evaluates FDA-approved companion diagnostics products that are commercialized in the U.S. as well as other regions. In addition, the study also includes companion diagnostics products that have received approvals for commercialization from the European Medicines Agency (EMA), Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA), and National Medical Products Administration (NMPA; formerly known as China Food and Drug Administration or the CFDA).

Market Segmentation

The global companion diagnostics market segmentation (on the basis of manufacturing) is further segmented on the basis of technology, application, and region.

The global companion diagnostics market segmentation (on the basis of technology) is segmented into polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and next-generation sequencing (NGS).

The global companion diagnostics market segmentation (on the basis of application) is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, stomach cancer, and melanoma.

The global companion diagnostics market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World.

Key Companies in the Global Companion Diagnostics Market

The key manufacturers who have been contributing significantly to the global companion diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, bioMerieux S.A., Danaher Corporation, DiaCarta, Inc., F. Hoffmann-La Roche Ltd, ICON plc, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., Novogene Corporation, QIAGEN N.V., Thermo Fisher Scientific Inc among others.

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report
  • 2.3 Global Companion Diagnostics Market: Research Methodology

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Iceberg Analysis - Global Companion Diagnostics Market
  • 4.3 Impact Analysis
  • 4.4 Market Drivers
    • 4.4.1 Growing Incidence of Cancer
      • 4.4.1.1 Better Treatment Assurance
      • 4.4.1.2 Diagnostic and Treatment Availability for All Forms of Cancer
    • 4.4.2 Growing Demand for Precision Medicine
      • 4.4.2.1 Adverse Drug Reactions
      • 4.4.2.2 Boost in Predictive Biomarker Discovery
    • 4.4.3 Co-Development of Drugs and Diagnostics
  • 4.5 Market Restraints
    • 4.5.1 Uncertain Reimbursement Scenario
    • 4.5.2 Companion Diagnostics Leakage in Oncology
    • 4.5.3 Weak Synchronization between Therapeutics and Diagnostics in Marketing and Distribution Channels
  • 4.6 Market Opportunities
    • 4.6.1 New Indication Areas
    • 4.6.2 Next-Generation Sequencing Accelerating Targeted Gene Therapy
    • 4.6.3 Data Science for Companion Diagnostics Applications

5 Industry Insights

  • 5.1 Legal Requirements and Framework by the FDA
  • 5.2 Legal Requirements and Framework by the EMA
  • 5.3 Legal Requirements and Framework by the MHLW

6 Competitive Landscape

  • 6.1 Mergers and Acquisitions
  • 6.2 Product Launches and Product Updates
  • 6.3 Synergistic Activities
  • 6.4 Business Expansion Activities and Others
  • 6.5 Product Approvals
  • 6.6 Market Share Analysis
  • 6.7 Opportunity Mapping
    • 6.7.1 By Technology
    • 6.7.2 By Application Area
    • 6.7.3 By Region

7 Global Companion Diagnostics Market Overview

  • 7.1 Classification of Companion Diagnostics (CDx)
  • 7.2 CDx in a Historical Perspective
  • 7.3 Constituents for Companion Diagnostics (CDx) Development
  • 7.4 Significant Applications of Companion Diagnostics (CDx)
  • 7.5 Companion Diagnostics (CDx): Future Potential

8 Global Companion Diagnostics Market (by Technology)

  • 8.1 Overview
  • 8.2 Polymerase Chain Reaction (PCR)
  • 8.3 Immunohistochemistry (IHC)
  • 8.4 In-Situ Hybridization (ISH)
  • 8.5 Next Generation Sequencing (NGS)

9 Global Companion Diagnostics Market (by Application Area)

  • 9.1 Overview
  • 9.2 Lung Cancer
  • 9.3 Breast Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Leukemia
  • 9.6 Stomach Cancer
  • 9.7 Melanoma
  • 9.8 Other Application Areas

10 Global Companion Diagnostics Market, (by Region)

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 Key Products Marketed
    • 10.2.2 U.S.
    • 10.2.3 Canada
  • 10.3 Europe
    • 10.3.1 Key Products Marketed
    • 10.3.2 Germany
    • 10.3.3 France
    • 10.3.4 U.K.
    • 10.3.5 Italy
    • 10.3.6 Spain
    • 10.3.7 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Key Products Marketed
    • 10.4.2 China
    • 10.4.3 Japan
    • 10.4.4 Australia
    • 10.4.5 India
    • 10.4.6 Singapore
    • 10.4.7 Rest-of-APAC
  • 10.5 Rest-of-the-World

11 Company Profiles

  • 11.1 Overview
  • 11.2 Abbott Laboratories
    • 11.2.1 Company Overview
    • 11.2.2 Role of Abbott Laboratories in the Global Companion Diagnostics Market
    • 11.2.3 Financials
    • 11.2.4 Key Insights About Financial Health of the Company
    • 11.2.5 SWOT Analysis
  • 11.3 Agilent Technologies, Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Role of Agilent Technologies, Inc. in the Global Companion Diagnostics Market
    • 11.3.3 Financials
    • 11.3.4 Key Insights About Financial Health of the Company
    • 11.3.5 SWOT Analysis
  • 11.4 ARUP Laboratories
    • 11.4.1 Company Overview
    • 11.4.2 Role of ARUP Laboratories in the Global Companion Diagnostics Market
    • 11.4.3 SWOT Analysis
  • 11.5 bioMerieux S.A.
    • 11.5.1 Company Overview
    • 11.5.2 Role of bioMerieux S.A. in the Global Companion Diagnostics Market
    • 11.5.3 Financials
    • 11.5.4 Key Insights About Financial Health of the Company
    • 11.5.5 SWOT Analysis
  • 11.6 Danaher Corporation
    • 11.6.1 Company Overview
    • 11.6.2 Role of Danaher Corporation in the Global Companion Diagnostics Market
    • 11.6.3 Financials
    • 11.6.4 Key Insights About Financial Health of the Company
    • 11.6.5 SWOT Analysis
  • 11.7 DiaCarta, Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Role of DiaCarta, Inc. in the Global Companion Diagnostics Market
    • 11.7.3 SWOT Analysis
  • 11.8 F. Hoffmann-La Roche Ltd
    • 11.8.1 Company Overview
    • 11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Companion Diagnostics Market
    • 11.8.3 Financials
    • 11.8.4 Key Insights About Financial Health of the Company
    • 11.8.5 SWOT Analysis
  • 11.9 ICON plc (MolecularMD Corporation)
    • 11.9.1 Company Overview
    • 11.9.2 Role of ICON plc in the Global Companion Diagnostics Market
    • 11.9.3 Financials
    • 11.9.4 SWOT Analysis
  • 11.10 Illumina, Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Role of Illumina, Inc. in the Global Companion Diagnostics Market
    • 11.10.3 Financials
    • 11.10.4 Key Insights About Financial Health of the Company
    • 11.10.5 SWOT Analysis
  • 11.11 Invivoscribe Technologies, Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Role of Invivoscribe Technologies, Inc. in the Global Companion Diagnostics Market
    • 11.11.3 SWOT Analysis
  • 11.12 Myriad Genetics, Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Role of Myriad Genetics, Inc. in the Global Companion Diagnostics Market
    • 11.12.3 Financials
    • 11.12.4 SWOT Analysis
  • 11.13 Novogene Corporation
    • 11.13.1 Company Overview
    • 11.13.2 Role of Novogene Corporation in the Global Companion Diagnostics Market
    • 11.13.3 SWOT Analysis
  • 11.14 QIAGEN N.V.
    • 11.14.1 Company Overview
    • 11.14.2 Role of QIAGEN N.V. in the Global Companion Diagnostics Market
    • 11.14.3 Financials
    • 11.14.4 Key Insights About Financial Health of the Company
    • 11.14.5 SWOT Analysis
  • 11.15 Thermo Fisher Scientific Inc.
    • 11.15.1 Company Overview
    • 11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Companion Diagnostics Market
    • 11.15.3 Financials
    • 11.15.4 Key Insights About Financial Health of the Company
    • 11.15.5 SWOT Analysis